NYSE:ANRO
Alto Neuroscience, Inc.
Alto Neuroscience, Inc. reported net income of −$63.2M in fiscal 2025. Free cash flow was −$51.8M, and the diluted share count rose 17.3%.Summary generated from Alto Neuroscience, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−41.8%
Debt / equity0.11
Free cash flow−$51.8M
FCF marginn/a
Share count change+17.3%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | n/a | n/a | n/a |
| Operating income | −38 | −69 | −66 |
| Net income | −36 | −61 | −63 |
| Free cash flow | −34 | −49 | −52 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 4Insider transaction report
Oct 1, 2026 - 8-KDirector or officer change
Aug 27, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026 - 8-KEntry into a material agreement
Jul 14, 2026 - 8-KResults of operations and financial condition
Jul 13, 2026 - 8-KDirector or officer change
May 28, 2026